These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 30918106)

  • 21. Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer.
    Aggarwal R; Rydzewski NR; Zhang L; Foye A; Kim W; Helzer KT; Bakhtiar H; Chang SL; Perry MD; Gleave M; Reiter RE; Huang J; Evans CP; Alumkal JJ; Lang JM; Yu M; Quigley DA; Sjöström M; Small EJ; Feng FY; Zhao SG
    JAMA Oncol; 2021 Nov; 7(11):1644-1652. PubMed ID: 34554200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature.
    Singhal U; Wang Y; Henderson J; Niknafs YS; Qiao Y; Gursky A; Zaslavsky A; Chung JS; Smith DC; Karnes RJ; Chang SL; Feng FY; Palapattu GS; Taichman RS; Chinnaiyan AM; Tomlins SA; Morgan TM
    Mol Cancer Res; 2018 Apr; 16(4):643-654. PubMed ID: 29453313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer.
    Chou J; Egusa EA; Wang S; Badura ML; Lee F; Bidkar AP; Zhu J; Shenoy T; Trepka K; Robinson TM; Steri V; Huang J; Wang Y; Small EJ; Chan E; Stohr BA; Ashworth A; Delafontaine B; Rottey S; Cooke KS; Hashemi Sadraei N; Yu B; Salvati M; Bailis JM; Feng FY; Flavell RR; Aggarwal R
    Cancer Res; 2023 Jan; 83(2):301-315. PubMed ID: 36351060
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuroendocrine cells of prostate cancer: biologic functions and molecular mechanisms.
    Huang YH; Zhang YQ; Huang JT
    Asian J Androl; 2019; 21(3):291-295. PubMed ID: 30924452
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate cancer: Multilayered mutation analysis indicates divergent clonal evolution.
    Thoma C
    Nat Rev Urol; 2016 Apr; 13(4):179. PubMed ID: 26902334
    [No Abstract]   [Full Text] [Related]  

  • 26. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
    Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
    Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genome-wide integrated analyses of androgen receptor signaling in prostate cancer based on high-throughput technology.
    Horie-Inoue K; Inoue S
    Curr Drug Targets; 2013 Apr; 14(4):472-80. PubMed ID: 23410126
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.
    Azad AA; Volik SV; Wyatt AW; Haegert A; Le Bihan S; Bell RH; Anderson SA; McConeghy B; Shukin R; Bazov J; Youngren J; Paris P; Thomas G; Small EJ; Wang Y; Gleave ME; Collins CC; Chi KN
    Clin Cancer Res; 2015 May; 21(10):2315-24. PubMed ID: 25712683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MiR-644a Disrupts Oncogenic Transformation and Warburg Effect by Direct Modulation of Multiple Genes of Tumor-Promoting Pathways.
    Ebron JS; Shankar E; Singh J; Sikand K; Weyman CM; Gupta S; Lindner DJ; Liu X; Campbell MJ; Shukla GC
    Cancer Res; 2019 Apr; 79(8):1844-1856. PubMed ID: 30808676
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer.
    Chen WY; Zeng T; Wen YC; Yeh HL; Jiang KC; Chen WH; Zhang Q; Huang J; Liu YN
    Cancer Lett; 2019 Jan; 440-441():35-46. PubMed ID: 30312731
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SF3B2-Mediated RNA Splicing Drives Human Prostate Cancer Progression.
    Kawamura N; Nimura K; Saga K; Ishibashi A; Kitamura K; Nagano H; Yoshikawa Y; Ishida K; Nonomura N; Arisawa M; Luo J; Kaneda Y
    Cancer Res; 2019 Oct; 79(20):5204-5217. PubMed ID: 31431456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular model for neuroendocrine prostate cancer progression.
    Chen R; Dong X; Gleave M
    BJU Int; 2018 Oct; 122(4):560-570. PubMed ID: 29569310
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression pattern of androgen receptors, AR-V7 and AR-567es, in circulating tumor cells and paired plasma-derived extracellular vesicles in metastatic castration resistant prostate cancer.
    Strati A; Zavridou M; Bournakis E; Mastoraki S; Lianidou E
    Analyst; 2019 Nov; 144(22):6671-6680. PubMed ID: 31596277
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicopathological and genetic analyses of small cell neuroendocrine carcinoma of the prostate: Histological features for accurate diagnosis and toward future novel therapies.
    Ida A; Okubo Y; Kasajima R; Washimi K; Sato S; Yoshioka E; Osaka K; Suzuki T; Yamamoto Y; Yokose T; Kishida T; Miyagi Y
    Pathol Res Pract; 2022 Jan; 229():153731. PubMed ID: 34952423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer.
    Siu MK; Chen WY; Tsai HY; Chen HY; Yin JJ; Chen CL; Tsai YC; Liu YN
    Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):172-178. PubMed ID: 28220803
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Androgen deprivation modulates gene expression profile along prostate cancer progression.
    Volante M; Tota D; Giorcelli J; Bollito E; Napoli F; Vatrano S; Buttigliero C; Molinaro L; Gontero P; Porpiglia F; Tucci M; Papotti M; Berruti A; Rapa I
    Hum Pathol; 2016 Oct; 56():81-8. PubMed ID: 27342909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer.
    Gupta S; Hovelson DH; Kemeny G; Halabi S; Foo WC; Anand M; Somarelli JA; Tomlins SA; Antonarakis ES; Luo J; Dittamore RV; George DJ; Rothwell C; Nanus DM; Armstrong AJ; Gregory SG
    Genes Chromosomes Cancer; 2020 Apr; 59(4):225-239. PubMed ID: 31705765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel AR translational regulator lncRNA LBCS inhibits castration resistance of prostate cancer.
    Gu P; Chen X; Xie R; Xie W; Huang L; Dong W; Han J; Liu X; Shen J; Huang J; Lin T
    Mol Cancer; 2019 Jun; 18(1):109. PubMed ID: 31221168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.
    Dardenne E; Beltran H; Benelli M; Gayvert K; Berger A; Puca L; Cyrta J; Sboner A; Noorzad Z; MacDonald T; Cheung C; Yuen KS; Gao D; Chen Y; Eilers M; Mosquera JM; Robinson BD; Elemento O; Rubin MA; Demichelis F; Rickman DS
    Cancer Cell; 2016 Oct; 30(4):563-577. PubMed ID: 27728805
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Androgen receptor signaling regulates the transcriptome of prostate cancer cells by modulating global alternative splicing.
    Shah K; Gagliano T; Garland L; O'Hanlon T; Bortolotti D; Gentili V; Rizzo R; Giamas G; Dean M
    Oncogene; 2020 Sep; 39(39):6172-6189. PubMed ID: 32820253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.